(Q57396207)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Frederik Persson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

5

Steven M Haffner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Hans-Henrik Parving

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Barry M Brenner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Dick de Zeeuw

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Scott D Solomon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Nish Chaturvedi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Maria Nicolaides

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Alexia Richard

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Zhihua Xiang

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Juergen Armbrecht

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Marc A Pfeffer

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

ALTITUDE Investigators

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

14 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Renin-Angiotensin-Aldosterone System

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

387-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

High glucose and renin release: the role of succinate and GPR91.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

The circadian clock in the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1470320311434818

21 January 2018

Identifiers

DOI

10.1177/1470320311434818

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22333485%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference